CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 464 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01297504
NCT01297504N/ACompleted
CompareCT.gov

A One-Year Observational Study of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America

AbbVie (prior sponsor, Abbott)·observational·Posted Feb 16, 2011·Updated Oct 1, 2014

In Brief

An observational study for Respiratory Syncytial Virus Infection. Completed, enrolled 464 participants across 24 sites in 7 countries.

Detailed Summary

The study was designed to gather information regarding the use of palivizumab for the prophylaxis for respiratory syncytial virus (RSV) infection in high-risk infants in selected countries within Latin America.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus Infection
CountriesArgentina, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
CollaboratorsFundasamin (Argentina)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 16, 2011
Enrollment StartFeb 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.4 years ago